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Abstract Advanced prostate cancer is frequently accompanied by the development of metastasis to bone. In the
past, prostate cancer bone metastases were characterized as being osteoblastic (i.e., increasing bone density) based on
radiographs. However, emerging evidence suggests that development of prostate cancer bone metastases requires
osteoclastic activity in addition to osteoblastic activity. The complexities of how prostate tumor cells influence bone
remodeling are just beginning to be elucidated. Prostate cancer cells produce a variety of pro-osteoblastic factors that
promote bone mineralization. For example, both bone morphogenetic proteins and endothelin-1 have well recognized
pro-osteoblastic activities and are produced by prostate cancer cells. In addition to factors that enhance bone
mineralization prostate cancer cells produced factors that promote osteoclast activity. Perhaps the most critical pro-
osteoclastogenic factor produced by prostate cancer cells is receptor activator of NFkB ligand (RANKL), which has been
shown to be required for the development of osteoclasts. Blocking RANKL results in inhibiting prostate cancer-induced
osteoclastogenesis and inhibits development andprogressionof prostate tumor growth inbone. These findings suggest that
targeting osteoclast activity may be of therapeutic benefit. However, it remains to be defined how prostate cancer cells
synchronize the combination of osteoclastic and osteoblastic activity. We propose that as the bone microenvironment is
changed by the developing cancer, this in turn influences the prostate cancer cells’ balance between pro-osteoclastic and
pro-osteoblastic activity. Accordingly, the determination of how the prostate cancer cells and bone microenvironment
crosstalk are important to elucidate howprostate cancer cells modulate bone remodeling. J. Cell. Biochem. 91: 718–729,
2004.  2003 Wiley-Liss, Inc.
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Bone is the most frequent site of prostate
carcinoma metastasis with skeletal metastases
identified at autopsy in up to 90% of patients
dying from prostate carcinoma [Abrams et al.,
1950; Rana et al., 1993; Bubendorf et al.,
2000]. Skeletal metastasis results in significant
complications including bone pain, impaired
mobility, pathological fracture, spinal cord
compression, and symptomatic hypercalcemia
[Galasko, 1986; Coleman, 1997; Moul and
Lipo, 1999]. Despite advances in the diagnosis
and management of prostate carcinoma,
advanced disease with skeletal metastasis
remains incurable. Current therapeutic modal-
ities are mostly palliative, and include hormo-
nal therapy, pharmacological management of
bone pain, radiotherapy for pain, and spinal
cord compression [Szostak and Kyprianou,
2000], various chemotherapy regimens, and
the use of bisphosphonates to inhibit osteoclast
activity [Papapoulos et al., 2000]. In spite of the
severe complications of prostate carcinoma
skeletal metastasis, there has not been much
advance in the therapeutic arena to prevent or
diminish these lesions. It is critical that a solid
understanding of the pathophysiology of pros-
tate carcinoma skeletal metastatic process is
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developed to provide the basis for creating
strategies to prevent or diminish their occur-
rence and associated complications.
There are many challenges that encompass
determining the mechanisms that contribute to
the selective development ofCaP in bone [Lange
and Vessella, 1998; Rosol, 2000]. These include
mechanisms of homing to bone and tumor cell
attachment at the bone endothelial site. How-
ever, once in the bone, CaP tumors have patho-
biology that appears to be somewhat unique to
cancer skeletal metastases. Specifically, CaP
skeletal metastases are most often radiogra-
phically characterized as osteoblastic (i.e.,
increased mineral density at the site of the
lesion) as opposed to osteolytic. Other tumors,
such as breast cancer, can form osteoblastic
lesions; however, these occur less frequently
[Munk et al., 1997; Yamashita et al., 2000]. In
spite of the radiographic osteoblastic appear-
ance it is clear from histological evidence that
CaP metastases form a heterogeneous mixture
of osteolytic and osteoblastic lesions although
osteoblastic lesions are predominant [Urwin
et al., 1985; Percival et al., 1987; Berruti et al.,
1996; Vinholes et al., 1996; Roudier et al., 2000].
Recent evidence shows that osteoblastic metas-
tases formontrabecularboneat sitesofprevious
osteoclastic resorption, and that such resorp-
tion may be required for subsequent osteoblas-
tic bone formation [Carlin and Andriole, 2000;
Zhang et al., 2001]. These findings suggest that
CaP induces boneproduction throughanoverall
increase in bone remodeling, which in the non-
pathologic state is a balance between osteoclast
resorption of bone, followed by osteoblast-medi-
ated replacement of resorbed bone (reviwed in
Boyce et al., 1999a; Karsenty, 2000; Parfitt,
2000). The mechanisms through which CaP
cells promote bone mineralization or bone
resorption remain poorly understood. Dissect-
ing these mechanisms should help identify
molecular targets for therapeutic approaches
to prevent the damaging effects of CaP on the
skeleton and their associated complications.
THE PRO-OSTEOBLASTIC NATURE
OF PROSTATE CANCER
Histomorphometric evidence indicates that
sites of prostate carcinoma bone metastases
often have microscopic evidence of increased
bone production including increased osteoid
surface, osteoid volume, and mineralization
rates [Charhon et al., 1983; Clarke et al., 1993].
The histological findings are consistent with
clinical evidence that demonstrates increased
systemic markers of both bone production in
prostate carcinomapatients [Maeda et al., 1997;
Demers et al., 2000]. However, evidence that
osteoclast activity occurs is also found, which
suggests that prostate carcinoma induces bone
production through an overall increase in bone
remodeling. In the case of prostate carcinoma, it
appears the induction of osteoblast-mediated
mineralization eventually outweighs the incre-
ase in osteoclast resorption resulting in an over-
all formation of osteoblastic lesions. Although it
would seem that the increased bone production
would not decrease the bones mechanical pro-
perties (i.e., its strength) it actually weakens
the bone for the following reasons; mature,
healthy bone is formed of lamellar bone, which
consists of collagen bundles that are organized
in a tightly packed linear fashion resulting in
optimum bone strength. In contrast, prostate
carcinoma induces production of woven bone,
which is composed of loosely packed, randomly
oriented collagen bundles that produce bone
with suboptimal strength [Blomme et al., 1999;
Rosol, 2000]. The combination of inferior bone
production and underlying osteolysis leads to a
predisposition to fracture.
The mechanisms through which prostate
carcinoma cells promote bone mineralization
remain poorly understood. However, prostate
carcinoma cells produce a variety of factors that
have direct or indirect osteogenic properties
(Table I) (reviewed in Goltzman et al., 1992;
Yoneda, 1998; Boyce et al., 1999b; Deftos, 2000).
Some of these factors, such as bone morphoge-
netic proteins (BMP) [Harris et al., 1994;
Autzen et al., 1998; Hullinger et al., 2000] and
enodothlin-1 (ET-1) [Nelson et al., 1995] may
directly stimulate differentiation of osteoblast
precursors to mature mineral-producing osteo-
blasts [Kimura et al., 1992] or induce osteoblast
protein production [Hullinger et al., 2000].
Other factors such as parathyroid hormone-
related protein (PTHrP) may work through
inhibition of osteoblast apoptosis) [Karaplis
and Vautour, 1997; Cornish et al., 1999].
Additionally, there are proteins that may work
indirectly to enhance bone production, such as
the serine proteases, prostate specific antigen
(PSA), and urinary plasminogen activator
(uPA), which can activate latent forms of osteo-
genic proteins, such as transforming growth
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factor-b (TFG-b) [Killian et al., 1993; Rabbani
et al., 1997]. Finally, some molecules, such as
osteoprotegerin (OPG) [Simonet et al., 1997;
Guise, 2000;Honore et al., 2000; Lee et al., 2003]
and ET-1 (in a dual role with its osteoblast-
stimulating activity) [Chiao et al., 2000] can
enhance osteosclerosis through inhibiting
osteoclastogenesis. Other tumor types, such as
osteosarcoma, are also known to produce a
variety of osteoblastic factors [Wlosarski and
Reddi, 1987; Raval et al., 1996; Laitinen et al.,
1998]. With such a large number of factors, it is
difficult to determine which the key factor is,
and most likely several of these osteogenic
factors work in concert to produce maximal
bone production. We will highlight two of the
factors, BMPand endothelin-1 (ET-1), forwhich
there is currently themost evidence for a role in
prostate cancer-induced osteosclerosis.
BMP are members of the TFG-b superfamily.
More than 30BMPs have been identified to date
[Ducy and Karsenty, 2000]. While originally
discovered because of their ability to induced
new bone formation, BMPs are now recognized
to perform many functions, particularly in the
role of development, such as apoptosis, differ-
entiation, proliferation, and morphogenesis
(reviewed in Hogan, 1996; Reddi, 1997; Hall
and Miyake, 2000). BMPs are synthesized as
large precursor molecules that undergo proteo-
lytic cleavage to release the mature protein,
which form active hetero- or homodimers
[Wozney, 1992; Suzuki et al., 1997]. BMPs bind
to receptors (BMPR-IA and -IB) and a BMP
type II receptor (BMPR-II), which induces
Smad phosphorylation [Wrana, 2000] resulting
in modulation of gene regulation. Target genes
of BMPs include osteoblast proteins such as
OPG [Wan et al., 2001] and the osteoblast-
specific transcription factor Cbfa-1 [Tsuji et al.,
1998; Gori et al., 1999]. Several proteins that
antagonize BMP action have been identified.
For example, noggin and gremlin inhibit BMP-
2, -4, and -7 by binding to them [Zimmerman
et al., 1996;Merino et al., 1999; Abe et al., 2000].
Furthermore, the BMPs themselves regulate
their own inhibitors in an apparent negative
feedback mechanism [Nifuji and Noda, 1999;
Nifuji et al., 1999].
Many in vitro studies have demonstrated that
BMPs induce osteogenic differentiation includ-
ing the ability of BMP-7 (also called osteogenic
protein-1; OP-1) to induce osteogenic differen-
tiation of newborn rat calvarial cells and
rat osteosarcoma cells [Asahina et al., 1993;
Maliakal et al., 1994; Li et al., 1996]. The BMP’s
osteogenic properties appear to be specific to the
differentiation stage of the target cells. Specifi-
cally, BMPs can induce uncommitted stem cells
[Katagiri et al., 1990; Li et al., 1996; Yamaguchi
et al., 1996] andmyoblasts [Katagiri et al., 1997]
to express osteoblast parameters such as alka-
line phosphatase or osteocalcin expression
[Ducy et al., 2000; Karsenty, 2000]; whereas,
BMPs do not stimulate mature osteoblasts or
fibroblasts [Knutsen et al., 1993; Yamaguchi
et al., 1996; Kim et al., 1997; Groeneveld and
Burger, 2000] to increase expression of these
proteins. Examination of genetically modified
mice provides further evidence of the impor-
tance of BMP in bone development. The bmp7
homozygousnull condition inmice is apostnatal
lethal mutation and is associated with, in
addition to renal and ocular abnormalities,
retarded skeletal ossification [Jena et al., 1997].
In contrast, bmp6 null mice are viable and
fertile, and the skeletal elements of newborn
and adult mutants are indistinguishable from
wildtype [Solloway et al., 1998]. However, care-
ful examination of skeletogenesis in late gesta-
tion embryos reveals a consistent delay in
ossification strictly confined to the developing
sternum. Finally, mice with mutations of the
bmp5 gene have skeletal abnormalities and
inefficient fracture repair [Kingsley et al.,
1992]. Thus, taken together, these data provide
TABLE I. Osteogenic Factors Produced by Cancer Cells
Factor Reference
Bone morphogenetic proteins (BMP) [Bentley et al., 1992; Hullinger et al., 2000]
Endothelin-1 (ET-1) [Nelson et al., 1995; Nelson and Carducci, 2000]
Insulin-like growth factors (IGF) [Perkel et al., 1990; Pirtskhalaishvili and Nelson, 2000]
Interleukin-1 and -6 [Taguchi et al., 1998; Le Brun et al., 1999]
Osteoprotegerin (OPG) [Guise, 2000; Honore et al., 2000]
Parathyroid hormone-related peptide (PTHrP) [Karaplis and Vautour, 1997; Cornish et al., 1999]
Transforming growth factor-b(TFG-b) [Killian et al., 1993]
Urinary plasminogen activator (urokinase) [Goltzman et al., 2000]
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evidence that BMPs are important regulators of
the osteogenesis. Thus, dysregulation of their
expression in thebonemicroenvironmentwould
most likely impact bone remodeling.
A few studies have examined the expression
of BMPs in normal and neoplastic prostate
tissues. Using Northern analysis, Harris et al.
[1994] examined for BMP-2, 3, 4, and 6 mRNA
expression in human normal prostate and pro-
state carcinoma cell lines. They found that nor-
mal human prostate predominantly expressed
BMP-4. The androgen-dependent non-meta-
static LNCaP human prostate carcinoma cell
line produced very low to undetectable levels of
BMPs.Whereas, the aggressive androgen-inde-
pendent PC-3 cell line expressed very high
levels of BMP-3 and slightly lower levels of
BMP-2, -4, and -6 compared to normal cells, but
much higher than LNCaP cells. In support of
these results, Weber et al. [1998], using PCR
analysis, identified 16 (73%) of 22 prostate
carcinoma samples were positive for BMP-7
mRNA compared to eight (57%) of 14 normal
prostate tissue samples. In another PCR based
analysis, Bentley et al. [1992], found that
several BMPs were expressed in both benign
and malignant prostate tissue and in the PC3
and DU145 prostate carcinoma cell lines.
BMP-6 expression was detected in the prostate
tissue of over 50% of patients with clinically
defined metastatic prostate adenocarcinoma,
but was not detected in non-metastatic or
benign prostate samples. In another study
focused on BMP-6 mRNA and protein expres-
sion, Barnes et al. [1995] observed that BMP-6
was produced by normal and neoplastic human
prostate (radical prostatectomy specimens and
human carcinoma cell lines DU145 and PC3).
However, BMP-6mRNAandprotein expression
was higher in prostate carcinoma as compared
with adjacent normal prostate, with higher-
grade tumors (Gleason score of 6 or more)
having greater BMP-6 immunostaining than
the lower-grade tumors (Gleason score of 4 or
less). These results were consistent with a later
study byHamdy et al. [1997], who reported that
BMP-6 mRNA expression was detected exclu-
sively in malignant epithelial cells in 20 of 21
patients (95%) with metastases, in 2 of 11
patients (18%) with localized cancer, and unde-
tectable in eight benign samples. Futhermore,
BMP-7 mRNA levels were found to be higher in
prostate cancer skeletal metastases than in
bone itself [Masuda et al., 2003]. In addition to
BMPs, there have been several reports on
prostate carcinoma expression of BMPR, it
appears that as prostate carcinoma progress,
the cells down-regulate their own expression of
BMPRs [Ide et al., 1997a; Kim et al., 2000],
which may be a protective mechanism as it has
been demonstrated that BMP-2 can inhibit
prostate carcinoma cell proliferation [Ide et al.,
1997b]. Taken together, these observations
demonstrate that prostate carcinoma cells pro-
duce increasing levels of BMPs as they progress
to a more aggressive phenotype and suggest
that the upregulation of BMP expression in
prostate carcinoma cells localized in the bone is
a critical component of the mechanism of
development of osteoblastic lesions at prostate
carcinoma metastatic sites.
Endothelins
Osteoblastic metastases occur in most pros-
tate cancers and frequently in other common
malignancies, such as breast cancer [Guise and
Mundy, 1998]. Many tumor-associated factors
have been proposed as mediators of the dis-
organized new bone formation at sites of meta-
stases, including insulin-like growth factors
(IGF)-1 and -2, transforming growth factor
(TGF) b, prostate-specific antigen (PSA), uroki-
nase-type plasminogen activator (UPA), fibro-
blast growth factors (FGF)-1 and -2, BMPs,
and endothelin-1 (ET-1) [Achbarou et al., 1994;
Thalmann et al., 1994; Nelson et al., 1995, 1996,
1999; Gingrich et al., 1996].
Accumulating evidence implicate ET-1 in the
pathogenesis of osteoblastic metastases. Yana-
gisawa et al. [1988] originally purified ET-1
from endothelial cells. ET-1 is a potent vasocon-
strictor, belonging to a family of three 21-amino-
acid peptides, with a variety of functions [La
and Reid, 1995]. The endothelins mediate their
effects through endothelin A (ETA) and endo-
thelin B (ETB) receptors. ETA receptors bind
ET-1 with ten times greater affinity than ET-3
while the B receptor binds all three endothelins
with equal affinity.
ET-1 has multiple effects on bone cells. It
stimulates mitogenesis in osteoblasts, which
express both ETA and ETB receptors [Takuwa
et al., 1990; Stern et al., 1995]. ET-1 decreases
osteoclastic bone resorption and osteoclast
motility [Alam et al., 1992]. Immunohistochem-
istry of bone detected ET-1 in osteocytes,
osteoblasts, and osteoclasts [Sasaki and Hong,
1993a,b].
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Nelson et al. [1995] suggested the link
between osteoblastic metastases, prostate can-
cer, and ET-1. They demonstrated that plasma
ET-1 concentrations were significantly higher
in men with advanced, hormone-refractory
prostate cancerwith bonemetastases compared
to men with organ-confined prostate cancer or
normal controls [Nelson et al., 1995]. However,
ET-1 concentrations were not correlated to
tumor burden in bone or to serum prostate-
specific antigen (PSA) concentrations.
Prostatic epithelium produces ET-1, and
high-affinity receptors are present throughout
the prostate gland [Nelson et al., 1995, 1996,
1999]. Amajority of prostate cancers at primary
as well as at metastatic sites express ET-1.
Exogenous ET-1 increases the proliferation of
prostate cancer as well as augmenting the
mitogenic effects of IGF-1, -2; platelet-derived
growth factor (PDGF); epidermal growth factor
(EGF) and FGF-2 on prostate cancer cells.
These effects are mediated via ETA receptors
[Nelson et al., 1996]. ETB receptor expression
was decreased in cancerous compared to normal
prostate and was low in the prostate cancer cell
lines PC3, DU 145, and LNCaP.
Breast cancers also express ET-1 and are the
next most common tumor to cause osteoblastic
metastases. Human breast cancer cells MCF-7,
T47-D, and MDA-MB-231 have been shown to
express the endothelin-processing enzyme
necessary to convert preproET-1 to ET-1 [Patel
and Schrey, 1995; Schrey and Patel, 1995;
Yorimitsu et al., 1995; Patel et al., 1997]. Thus,
substantial data implicate ET-1 in the patho-
genesis of osteoblastic metastases due to pros-
tate and breast cancers. However, a direct
demonstration of a causal role for ET-1 in bone
metastasis has not previously been reported.
Questions remain about whether ET-1 has
effects on bone formation in vivo, about the
specificity of its effects, and about whether the
increase in ET-1 observed in patients with
prostate cancer represents a causative factor.
The bulk of evidence for a pro-osteoblastic
metastatic effect of ET-1 has been derived from
breast cancer skeletal metastases. Recent evi-
dence indicates that breast cancer lines (ZR-75-
1, MCF-7, and T47D) all cause osteoblastic
metastases in female nude mice and produce
ET-1 [Yin et al., 2000]. Conditioned media from
these cell lines, as well as exogenous ET-1,
stimulated osteoblast proliferation and new
bone formation in cultures of mouse calvariae.
These effectswere inhibited bynonselective and
ETA, but not ETB, receptor antagonists. Mice
inoculated with ZR-75-1 and treated with oral
ABT-627, a selective ETA receptor antagonist
(2 or 20 mg/kg/day), had significantly fewer
bone metastases compared with untreated ZR-
75-1-mice. Bone histomorphometry revealed
that the untreated ZR-75-1-mice had greater
total bone area as well as new bone area
compared with ABT-627-treated ZR-75-1-mice
at either dose. Tumor burden in bone was
significantly less in ABT-627-treated mice. In
contrast, there was no effect of ABT-627 on
osteolytic bone metastases caused by ET-1-
negative breast cancer, MDA-MB-231. ETA
and ETB expression, determined by RT-PCR,
revealed that ZR-75-1 expressed neither ETA
nor ETB while MDA-MB-231 expressed both.
There was no effect of ABT-627 on (1) in vitro
growth of ZR-75-1 orMDA-MB-231 or (2) in vivo
growth of ZR-75-1 or MDA-MB-231 mammary
fat pad tumors. These data indicate that the
effects of ABT-627 to inhibit osteoblastic metas-
tases are not direct effects on these tumor cells,
but rather directed against the osteoblastic
response of tumor-produced ET-1. Collectively
these data suggest that tumor-produced ET-1
likely has a major role in the establishment of
osteoblastic bone metastases by stimulating
osteoblast proliferation and new bone forma-
tion. In terms of prostate cancer, atrasentan, an
antagonist of ET-1 receptor A, partially re-
versed primary murine osteoblast proliferation
induced by prostate cancer cells [Fizazi et al.,
2003], suggesting that ET-1 may play a role
in vivo. Blockade of the ETA receptor may be
useful for prevention and the treatment of
osteoblastic bone metastases due to breast or
prostate cancer.
In addition to production of pro-osteoblastic
factors, prostate cancer cells themselves gain an
osteoblast-like phenotype. The initial evidence
for this possibility was shown in a study that
demonstrated C4-2B prostate cancer cells
mineralized in vitro [Lin et al., 2001]. Further-
more, increased nuclear expression of the bone-
specific transcription factor Cbfa1 (also known
asRunx2,CCD,AML3,CCD1,OSF2)was found
in the C4-2B cells and blocking Cbfa1 activity
decreased the ability of C4-2B cells to miner-
alize in vitro. Additionally, mRNA and protein
of the osteoblast-active transcription factor
Cbfa1 were detected in prostate cancer tissues
and cell lines [Brubaker et al., 2003]. Finally, a
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specific Cbfa1: OSE2 (an osteoblast-specific cis-
acting element present in the osteocalcin pro-
moter) complex could be formed with PC-3
nuclear extracts. These data suggest that
prostate cancer cells may promote osteosclero-
sis directly, although direct evidence of this has
not been provided to date.
In summary, a variety of factorsmay promote
the osteoblastic nature of prostate cancer bone
metastases. Most likely no individual factor is
responsible for prostate cancer-induced osteo-
sclerosis, but rather several factors work in




In healthy adults, the regulated destruction
(resorption or lysis) of normal lamellar bone
matrix by large multinucleated osteoclasts is
tightly coupled to the consequent formation of
new bone by osteoblasts, such that lysis and
formation are balanced (reviewed inManolagas
and Jilka, 1995). However, in prostate cancer
bonemetastasis, bone lysis is stimulated at sites
of tumor growth and excess woven bone is
synthesized [Clarke et al., 1991]. This results
in a general increase in both bone turnover and
volume, although woven bone has less collagen
and therefore less tensile strength than normal
and is more susceptible to fracture. Evidence
suggests that lysis is a prerequisite for the
establishment of tumor cells in bone [Roland,
1958; Nielsen et al., 1991], therefore under-
standing the regulation of bone resorption may
suggestmechanisms throughwhich tumors can
develop in bone and may indicate novel ther-
apeutic targets.
In normal bone, osteoblastic cells regulate
osteoclastogenesis and osteoclast activity by
interacting with mononuclear hematopoietic
osteoclast precursors [Roodman, 1996]. The
molecular mediators of this interaction were
shown to be the osteoblast-expressed proteins,
OPG and receptor activator of NFkB ligand
(RANKL). Binding of RANKL to the osteoclast
precursor-expressed RANK initiates a cascade
of intracellular signals that culminates in the
acquisition and activation of the osteoclast
phenotype [Lacey et al., 1998; Yasuda et al.,
1998a]. The absolute requirement of this inter-
action for osteoclastogenesis was shown by
the generation of transgenic rankl / and
rank / mice that developed severely hyper-
dense bones due to an absence of osteoclasts
[Dougall et al., 1999; Kong et al., 1999].
Furthermore, administration of soluble extra-
cellular RANKL to mice resulted in hypercalce-
mia and reduced bone volume, concomitant
with a doubling of osteoclast size [Lacey et al.,
1998]. The soluble glycoprotein OPG regulates
excessive bone resorption by acting as a soluble
decoy receptor for RANKL [Simonet et al.,
1997], and therefore neutralizes its interaction
with RANK, abrogating osteoclast formation,
activation, and survival in vitro [Yasuda et al.,
1998a,b] and in vivo [Lacey et al., 1998]. The
crucial role of OPG in bone remodeling was
demonstrated using transgenic opg / mice,
which showed uncontrolled bone resorption and
severe osteoporosis [Mizuno et al., 1998]. These
studies suggest that the balance between
RANKLandOPGdetermines the extent of bone
resorption, in that a relative decrease in OPG
results in excessive resorption and a relative
increase in OPG inhibits resorption.
Recentwork has shown that the expression of
OPG, RANKL, and/or RANK is dysregulated in
a number of cancers in bone, including osteo-
clastoma [Atkins et al., 2000] and prostate
cancer [Brown et al., 2001], suggesting that
these proteins may be involved in tumor-
mediated bone destruction. Breast cancer cell
lineswere shown to expressOPGandRANKbut
not RANKL [Thomas et al., 1999]. However, co-
culture with hematopoietic bone marrow cells
and osteoblasts resulted in a net increase in
RANKL expression, suggesting an indirect
mechanism through which localized bone lysis
may occur in breast cancer bone metastasis, by
activation of osteoclast precursors [Thomas
et al., 1999]. This was supported using amurine
in vitro model in which interactions between
mouse breast cancer cells and bonemarrowcells
similarly resulted in a net increase in RANKL
activity [Chikatsu et al., 2000]. The cancer–
stromal interaction is also critical in multiple
myeloma, where co-culture produced a net
increase in RANKL expression and in osteo-
clastogenesis that was inhibited by addition of
soluble RANK [Pearse et al., 2001]. The produc-
tion of active soluble RANKL by prostate cancer
cells in vitro has been implicated as a mechan-
ism through which prostate cancer cells can
directly initiate osteoclastogenesis and there-
fore stimulate bone resorption [Zhang et al.,
2001].
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Several exciting and provocative studies have
examined the therapeutic uses of soluble RANK
and OPG in the treatment of hematological and
solid tumors in bone. As a fusion protein with
human IgG, RANKhas proven efficacious in the
inhibition of bone resorption in a mouse model
of humoral hypercalcemia of malignancy as
induced by PTHrP administration [Oyajobi
et al., 2001], and in the prevention of mye-
loma-induced osteoclastic bone destruction in a
SCID-human model [Pearse et al., 2001].
In vitro experiments treating osteoclastoma-
derived cells with OPG reduced the number of
mature osteoclasts and inhibited bone resorp-
tion [Atkins et al., 2001]. Dramatic decreases in
the numbers of mature osteoclasts and in the
size and/or number of lesions in bone were
observed following the treatment with OPG
of mice carrying human breast cancer cells
[Morony et al., 2001], murinemultiplemyeloma
[Croucher et al., 2001], and human prostate
cancer cells [Zhang et al., 2001]. In human
prostate cancer cells, OPGhas been shown to be
a survival factor through its ability to inhibit
TRAIL-mediated apoptosis [Holen et al., 2002].
Importantly, treatmentwithOPGhas also been
demonstrated to block pain-related behavior in
mice carrying bone cancers [Honore et al., 2000;
Luger et al., 2001]. Overall, these studies
suggest that in bone metastatic tumors, inhibi-
tion of the primary resorptive stage may be
sufficient to inhibit tumor establishment and
halt progressionofdisease, even in those tumors
that have primarily an osteoblastic phenotype.
However, one prostate cancer cell line, LAPC-9,
was demonstrated to not produce RANKL, but
rather producedOPG [Lee et al., 2003]. This cell
line produced osteoblastic tumor when injected
into mouse tibia. The osteoblastic tumors did
not appear to have osteoclastic activity during
their early development phase, but developed
osteoclastic activity by 6 weeks. These results
bring into question the requirement for osteo-
clastic activity for the initial establishment of
the prostate tumors inbone.Further support for
this possibility was the observation that a
bisphosphonate, zoledronic acid, did not dimi-
nish development of LAPC-9 cells injected into
the tibia of mice; whereas it did decrease
development of osteolytic PC-3 cells [Lee et al.,
2002]. While studies are at an early stage at
present, it appears that therapeutic targeting of
the OPG/RANKL/RANK proteins holds great
promise for at least therapy of bone metastases
and perhaps may prevent establishment and
progression of bone metastases.
A MODEL FOR PROSTATE CANCER’S
EFFECT ON BONE REMODELING
From these observations, we propose a model
for how prostate cancer cells influence bone
remodeling. In order to account the apparently
contrasting ability of prostate cancer cells to be
both pro-osteoblastic and pro-osteolytic several
aspects of the metastases need to be taken into
account. These include the bone microenviron-
ment the tumor cells are exposed to (reviewed in
Cooper et al., 2003) and the temporal progres-
sion of the cancer. Based on these parameters,
we propose (Fig. 1) that when prostate cancer
cells metastasize to bone, they initially induce
osteoclastogenesis and bone resorption. As bone
is broken down, the extracellular matrix
releases a variety of growth factors (reviewed
in Guise and Mundy, 1998 #8470) that act in a
paracrine fashion on the prostate tumor cells
and diminish their ability to induce osteoclas-
togenesis, while promoting their ability to grow
and induce osteoblastic activity. This model is
consistent with various observations including
the ability of anti-osteoclastogenic agents to
inhibit establishment of tumor in bone and the
mixture of osteolytic and osteoblastic features
identified in clinical prostate cancer bone
metastases, even within one patient. Unfortu-
nately, proving this hypothesis is challenging
for several reasons including that there are
currently no animal models that recapitulate
spontaneous clinical prostate cancer bone
metastases.
The biology of prostate cancer bone metasta-
sis has received increased attention in the last
few years. The resulting data point to a
complicated system with multiple interacting
proteins and pathways. Thus, while dissecting
individual protein factor pathways (e.g., BMPs)
is important, eventually a synthesis of how
these various pathwayswork together to impact
bone remodeling will be necessary to provide a
comprehensive understanding of the biology of
prostate cancer bonemetastases.Along this line
of thought, clearly the bone microenvironment,
which is under constant change from the
influence of tumor cells, plays a role in the
establishment and progression of prostate can-
cer bone metastases. Thus, future studies are
needed to define the complex cross-talk between
724 Keller and Brown
the bone microenvironment and the prostate
cancer cells. In order to reach these goals,
development of appropriate research tools, such
as animal models and cells lines, that recapitu-
late human prostate cancer bone metastasis
biology, are needed to advance the field.
REFERENCES
Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, O’Brien
CA, Economides AN, Stahl N, Jilka RL, Manolagas SC.
2000. Essential requirement of BMPs-2/4 for both
osteoblast and osteoclast formation in murine bone
marrow cultures from adult mice: Antagonism by noggin.
J Bone Miner Res 15:663–673.
Abrams H, Spiro R, Goldstein N. 1950. Metastases in
carcinoma. Cancer 3:74–85.
Achbarou A, Kaiser S, Tremblay G, Ste-Marie LG, Brodt P,
Goltzman D, Rabbani SA. 1994. Urokinase overproduc-
tion results in increased skeletal metastasis by prostate
cancer cells in vivo. Cancer Res 54:2372–2377.
Alam AS, Gallagher A, Shankar V, Ghatei MA, Datta HK,
Huang CL, Moonga BS, Chambers TJ, Bloom SR, Zaidi
M. 1992. Endothelin inhibits osteoclastic bone resorption
by a direct effect on cell motility: Implications for the
vascular control of bone resorption. Endocrinology 130:
3617–3624.
Asahina I, Sampath TK, Nishimura I, Hauschka PV. 1993.
Human osteogenic protein-1 induces both chondroblastic
and osteoblastic differentiation of osteoprogenitor cells
derived from newborn rat calvaria. J Cell Biol 123:921–
933.
Atkins GJ, Haynes DR, Graves SE, Evdokiou A, Hay S,
Bouralexis S, Findlay DM. 2000. Expression of osteoclast
differentiation signals by stromal elements of giant cell
tumors. J Bone Miner Res 15:640–649.
Atkins GJ, Bouralexis S, Haynes DR, Graves SE, Geary
SM, Evdokiou A, Zannettino AC, Hay S, Findlay DM.
2001. Osteoprotegerin inhibits osteoclast formation and
bone resorbing activity in giant cell tumors of bone. Bone
28:370–377.
Autzen P, Robson CN, Bjartell A, Malcolm AJ, Johnson MI,
Neal DE, Hamdy FC. 1998. Bone morphogenetic protein
6 in skeletal metastases from prostate cancer and other
common human malignancies. Br J Cancer 78:1219–
1223.
Barnes J, Anthony CT, Wall N, Steiner MS. 1995. Bone
morphogenetic protein-6 expression in normal and
malignant prostate. World J Urol 13:337–343.
Bentley H, Hamdy FC, Hart KA, Seid JM, Williams JL,
Johnstone D, Russell RG. 1992. Expression of bone
morphogenetic proteins in human prostatic adenocarci-
noma and benign prostatic hyperplasia. Br J Cancer
66:1159–1163.
Berruti A, Piovesan A, Torta M, Raucci CA, Gorzegno G,
Paccotti P, Dogliotti L, Angeli A. 1996. Biochemical
evaluation of bone turnover in cancer patients with
bone metastases: Relationship with radiograph appear-
ances and disease extension. Br J Cancer 73:1581–
1587.
Blomme EA, Dougherty KM, Pienta KJ, Capen CC, Rosol
TJ, McCauley LK. 1999. Skeletal metastasis of prostate
adenocarcinoma in rats: Morphometric analysis and role
of parathyroid hormone-related protein. Prostate 39:
187–197.
Fig. 1. Model for how prostate cancer induces bone remodel-
ing. The prostate cancer cells initially (1) induce osteoclastogen-
esis and resorption ofmature lamellar bone. As the bonematrix is
destroyed, it releases growth factors (2) that induce prostate
cancer cells’ growth and alter their phenotype. The changing
bone microenvironment, enhances the prostate cancer cells’
production of osteoblastic factors (3) resulting in production of
woven bone. BMP, bone morphogenetic protein; CaP, prostate
cancer cell; ET-1, endothelin-1; IL-6, interleukin-6; RANKL,
receptor activator of NFkB ligand; TGF-b, transforming growth
factor b.
Prostate Cancer Metastases Induce Bone Remodeling 725
Boyce BF, Hughes DE, Wright KR, Xing L, Dai A. 1999a.
Recent advances in bone biology provide insight into the
pathogenesis of bone diseases. Lab Invest 79:83–94.
Boyce BF, Yoneda T, Guise TA. 1999b. Factors regulating
the growth of metastatic cancer in bone. Endocr Relat
Cancer 6:333–347.
Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M,
Vessella RL. 2001. Osteoprotegerin and rank ligand
expression in prostate cancer. Urology 57:611–616.
Brubaker KD, Vessella RL, Brown LG, Corey E. 2003.
Prostate cancer expression of runt-domain transcription
factor Runx2, a key regulator of osteoblast differentiation
and function. Prostate 56:13–22.
Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H,
Willi N, Gasser TC, Mihatsch MJ. 2000. Metastatic
patterns of prostate cancer: An autopsy study of 1,589
patients. Hum Pathol 31:578–583.
Carlin BI, Andriole GL. 2000. The natural history, skeletal
complications, and management of bone metastases in
patients with prostate carcinoma. Cancer 88:2989–2994.
Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A,
Edouard CM, Meunier PJ. 1983. Histomorphometric
analysis of sclerotic bonemetastases from prostatic carci-
noma special reference to osteomalacia. Cancer 51:918–
924.
Chiao JW, Moonga BS, Yang YM, Kancherla R, Mittelman
A, Wu-Wong JR, Ahmed T. 2000. Endothelin-1 from
prostate cancer cells is enhanced by bone contact which
blocks osteoclastic bone resorption. Br J Cancer 83:360–
365.
Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K,
Tsuda E, Ogata E, Fujita T. 2000. Interactions between
cancer and bone marrow cells induce osteoclast differ-
entiation factor expression and osteoclast-like cell for-
mation in vitro. BiochemBiophys Res Commun 267:632–
637.
Clarke NW, McClure J, George NJ. 1991. Morphometric
evidence for bone resorption and replacement in prostate
cancer. Br J Urol 68:74–80.
Clarke NW, McClure J, George NJ. 1993. Osteoblast
function and osteomalacia in metastatic prostate cancer.
Eur Urol 24:286–290.
Coleman RE. 1997. Skeletal complications of malignancy.
Cancer 80:1588–1594.
Cooper CR, Chay CH, Gendernalik JD, Lee HL, Bhatia J,
Taichman RS, McCauley LK, Keller ET, Pienta KJ. 2003.
Stromal factors involved in prostate carcinoma metas-
tasis to bone. Cancer 97:739–747.
Cornish J, Callon KE, Lin C, Xiao C, Moseley JM, Reid IR.
1999. Stimulation of osteoblast proliferation by C-
terminal fragments of parathyroid hormone-related
protein. J Bone Miner Res 14:915–922.
Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K,
Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM,
Dunstan CR, Russell GR, Van Camp B, Vanderkerken K.
2001. Osteoprotegerin inhibits the development of osteo-
lytic bone disease in multiple myeloma. Blood 98:3534–
3540.
Deftos LJ. 2000. Prostate carcinoma: Production of bioac-
tive factors. Cancer 88:3002–3008.
Demers LM, Costa L, Lipton A. 2000. Biochemical markers
and skeletal metastases. Cancer 88:2919–2926.
Dougall WC, Glaccum M, Charrier K, Rohrbach K,
Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME,
Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman
D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J. 1999.
RANK is essential for osteoclast and lymph node
development. Genes Dev 13:2412–2424.
Ducy P, Karsenty G. 2000. The family of bone morphoge-
netic proteins. Kidney Int 57:2207–2214.
Ducy P, Schinke T, Karsenty G. 2000. The osteoblast:
A sophisticated fibroblast under central surveillance.
Science 289:1501–1504.
Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani
D, Olive M, Raymond KA, Janus TJ, Logothetis CJ,
Karsenty G, Navone NM. 2003. Prostate cancer cells–
osteoblast interaction shifts expression of growth/survi-
val-related genes in prostate cancer and reduces expres-
sion of osteoprotegerin in osteoblasts. Clin Cancer Res
9:2587–2597.
Galasko CS. 1986. Skeletal metastases. Clin Orthop 210:
18–30.
Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo
FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg
NM. 1996. Metastatic prostate cancer in a transgenic
mouse. Cancer Res 56:4096–4102.
Goltzman D, Bolivar I, Rabbani SA. 1992. Studies on the
pathogenesis of osteoblastic metastases by prostate
cancer. Adv Exp Med Biol 324:165–171.
Goltzman D, Karaplis AC, Kremer R, Rabbani SA. 2000.
Molecular basis of the spectrum of skeletal complications
of neoplasia. Cancer 88:2903–2908.
Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL. 1999.
Differentiation of human marrow stromal precursor
cells: Bone morphogenetic protein-2 increases OSF2/
CBFA1, enhances osteoblast commitment, and inhibits
late adipocyte maturation. J Bone Miner Res 14:1522–
1535.
Groeneveld EH, Burger EH. 2000. Bone morphogenetic
proteins in human bone regeneration. Eur J Endocrinol
142:9–21.
Guise TA. 2000. Molecular mechanisms of osteolytic bone
metastases. Cancer 88:2892–2898.
Guise TA, Mundy GR. 1998. Cancer and bone. Endocr Rev
19:18–54.
Hall BK, Miyake T. 2000. All for one and one for all:
Condensations and the initiation of skeletal develop-
ment. Bioessays 22:138–147.
Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE,
Robson CN. 1997. Immunolocalization and messenger
RNA expression of bone morphogenetic protein-6 in
human benign and malignant prostatic tissue. Cancer
Res 57:4427–4431.
Harris SE, Harris MA,Mahy P,Wozney J, Feng JQ,Mundy
GR. 1994. Expression of bone morphogenetic protein
messenger RNAs by normal rat and human prostate and
prostate cancer cells. Prostate 24:204–211.
Hogan BL. 1996. Bone morphogenetic proteins in develop-
ment. Curr Opin Genet Dev 6:432–438.
Holen I, Croucher PI, Hamdy FC, Eaton CL. 2002.
Osteoprotegerin (OPG) is a survival factor for human
prostate cancer cells. Cancer Res 62:1619–1623.
Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD,
Mach DB, O’Keefe PF, Ramnaraine ML, Clohisy DR,
Mantyh PW. 2000. Osteoprotegerin blocks bone cancer-
induced skeletal destruction, skeletal pain, and pain-
related neurochemical reorganization of the spinal cord.
Nat Med 6:521–528.
726 Keller and Brown
Hullinger TG, TaichmanRS, LinsemanDA, SomermanMJ.
2000. Secretory products from PC-3 and MCF-7 tumor
cell lines upregulate osteopontin in MC3T3-E1 cells.
J Cell Biochem 78:607–616.
Ide H, Katoh M, Sasaki H, Yoshida T, Aoki K, Nawa Y,
Osada Y, Sugimura T, Terada M. 1997a. Cloning of
human bone morphogenetic protein type IB receptor
(BMPR-IB) and its expression in prostate cancer in
comparison with other BMPRs published erratum
appears in Oncogene 1997 Aug 28;15(9):1121. Oncogene
14:1377–1382.
Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y,
Sugimura T, Terada M. 1997b. Growth regulation of
human prostate cancer cells by bone morphogenetic
protein-2. Cancer Res 57:5022–5027.
Jena N, Martin-Seisdedos C, McCue P, Croce CM. 1997.
BMP7 null mutation in mice: Developmental defects in
skeleton, kidney, and eye. Exp Cell Res 230:28–37.
Karaplis AC, Vautour L. 1997. Parathyroid hormone-
related peptide and the parathyroid hormone/para-
thyroid hormone-related peptide receptor in skeletal
development. Curr Opin Nephrol Hypertens 6:308–
313.
Karsenty G. 2000. Bone formation and factors affecting this
process. Matrix Biol 19:85–89.
Katagiri T, Yamaguchi A, Ikeda T, Yoshiki S, Wozney JM,
Rosen V, Wang EA, Tanaka H, Omura S, Suda T. 1990.
The non-osteogenic mouse pluripotent cell line,
C3H10T1/2, is induced to differentiate into osteoblastic
cells by recombinant human bone morphogenetic pro-
tein-2. Biochem Biophys Res Commun 172:295–299.
Katagiri T, Akiyama S, Namiki M, Komaki M, Yamaguchi
A, Rosen V, Wozney JM, Fujisawa-Sehara A, Suda T.
1997. Bone morphogenetic protein-2 inhibits terminal
differentiation of myogenic cells by suppressing the
transcriptional activity of MyoD and myogenin. Exp Cell
Res 230:342–351.
Killian CS, Corral DA, Kawinski E, Constantine RI. 1993.
Mitogenic response of osteoblast cells to prostate-specific
antigen suggests an activation of latent TGF-beta and a
proteolytic modulation of cell adhesion receptors. Bio-
chem Biophys Res Commun 192:940–947.
Kim KJ, Itoh T, Kotake S. 1997. Effects of recombinant
human bone morphogenetic protein-2 on human bone
marrow cells cultured with various biomaterials. J
Biomed Mater Res 35:279–285.
Kim IY, Lee DH, AhnHJ, Tokunaga H, SongW, Devereaux
LM, Jin D, Sampath TK, Morton RA. 2000. Expression of
bone morphogenetic protein receptors type-IA, -IB, and
-II correlates with tumor grade in human prostate cancer
tissues. Cancer Res 60:2840–2844.
Kimura G, Sugisaki Y, Masugi Y, Nakazawa N. 1992.
Calcification in human osteoblasts cultured in medium
conditioned by the prostatic cancer cell line PC-3 and
prostatic acid phosphatase. Urol Int 48:25–30.
Kingsley DM, Bland AE, Grubber JM, Marker PC, Russell
LB, Copeland NG, Jenkins NA. 1992. The mouse short
ear skeletal morphogenesis locus is associated with
defects in a bone morphogenetic member of the TGF
beta superfamily. Cell 71:399–410.
Knutsen R,Wergedal JE, Sampath TK, Baylink DJ, Mohan
S. 1993. Osteogenic protein-1 stimulates proliferation
and differentiation of human bone cells in vitro. Biochem
Biophys Res Commun 194:1352–1358.
Kong YY, Boyle WJ, Penninger JM. 1999. Osteoprotegerin
ligand: A common link between osteoclastogenesis,
lymph node formation, and lymphocyte development.
Immunol Cell Biol 77:188–193.
La M, Reid JJ. 1995. Endothelin-1 and the regulation of
vascular tone. Clin Exp Pharmacol Physiol 22:315–323.
Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR,
Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli
A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G,
Guo J, Delaney J, Boyle WJ. 1998. Osteoprotegerin
ligand is a cytokine that regulates osteoclast differentia-
tion and activation. Cell 93:165–176.
LaitinenM,Marttinen A, Aho AJ, LindholmTS. 1998. Bone
morphogenetic protein in bone neoplasms: Comparison of
different detection methods. Eur Surg Res 30:168–174.
Lange PH, Vessella RL. 1998. Mechanisms, hypotheses,
and questions regarding prostate cancer micrometas-
tases to bone. Cancer Metastasis Rev 17:331–336.
Le Brun G, Aubin P, Soliman H, Ropiquet F, Villette JM,
Berthon P, Creminon C, Cussenot O, Fiet J. 1999.
Upregulation of endothelin 1 and its precursor by IL-
1beta, TNF-alpha, and TGF-beta in the PC3 human
prostate cancer cell line. Cytokine 11:157–162.
Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X,
Wu J, Lieberman JR. 2002. Use of zoledronate to treat
osteoblastic versus osteolytic lesions in a severe-com-
bined-immunodeficient mouse model. Cancer Res 62:
5564–5570.
Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X,
Lieberman JR. 2003. Differences in the cytokine pro-
files associated with prostate cancer cell induced osteo-
blastic and osteolytic lesions in bone. J Orthop Res 21:
62–72.
Li IW, Cheifetz S, McCulloch CA, Sampath KT, Sodek J.
1996. Effects of osteogenic protein-1 (OP-1, BMP-7) on
bone matrix protein expression by fetal rat calvarial
cells are differentiation stage specific. J Cell Physiol 169:
115–125.
Lin DL, Tarnowski CP, Zhang J, Dai J, Rohn E, Patel AH,
Morris MD, Keller ET. 2001. Bone metastatic LNCaP-
derivative C4-2B prostate cancer cell line mineralizes
in vitro. Prostate 47:212–221.
Luger NM, Honore P, Sabino MA, Schwei MJ, Rogers SD,
Mach DB, Clohisy DR, Mantyh PW. 2001. Osteoprote-
gerin diminishes advanced bone cancer pain. Cancer Res
61:4038–4047.
Maeda H, KoizumiM, Yoshimura K, Yamauchi T, Kawai T,
Ogata E. 1997. Correlation between bone metabolic
markers and bone scan in prostatic cancer. J Urol
157:539–543.
Maliakal JC, Asahina I, Hauschka PV, Sampath TK. 1994.
Osteogenic protein-1 (BMP-7) inhibits cell proliferation
and stimulates the expression of markers characteristic
of osteoblast phenotype in rat osteosarcoma (17/2.8) cells.
Growth Factors 11:227–234.
Manolagas SC, Jilka RL. 1995. Bone marrow, cytokines,
and bone remodeling. Emerging insights into the patho-
physiology of osteoporosis. New Engl J Med 332:305–
311.
Masuda H, Fukabori Y, Nakano K, Takezawa Y, T CS,
Yamanaka H. 2003. Increased expression of bone mor-
phogenetic protein-7 in bone metastatic prostate cancer.
Prostate 54:268–274.
Prostate Cancer Metastases Induce Bone Remodeling 727
Merino R, Rodriguez-Leon J, Macias D, Ganan Y,
Economides AN, Hurle JM. 1999. The BMP antagonist
gremlin regulates outgrowth, chondrogenesis, and pro-
grammed cell death in the developing limb. Development
126:5515–5522.
Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N,
Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S,
Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E,
Morinaga T, Higashio K, Ozawa H. 1998. Severe
osteoporosis inmice lacking osteoclastogenesis inhibitory
factor/osteoprotegerin. Biochem Biophys Res Commun
247:610–615.
Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR,
Kostenuik PJ. 2001. Osteoprotegerin inhibits osteolysis
and decreases skeletal tumor burden in syngeneic and
nude mouse models of experimental bone metastasis.
Cancer Res 61:4432–4436.
Moul JW, Lipo DR. 1999. Prostate cancer in the late 1990s:
Hormone refractory disease options. Urol Nurs 19:125–
31; quiz 132-3.
Munk PL, Poon PY, O’Connell JX, Janzen D, Coupland D,
Kwong JS, Gelmon K, Worsley D. 1997. Osteoblastic
metastases from breast carcinoma with false-negative
bone scan. Skeletal Radiol 26:434–437.
Nelson JB, CarducciMA. 2000. The role of endothelin-1 and
endothelin receptor antagonists in prostate cancer. BJU
Int 85(Suppl 2):45–48.
Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi
S, Eisenberger MA, Simons JW. 1995. Identification of
endothelin-1 in the pathophysiology of metastatic ade-
nocarcinoma of the prostate. Nat Med 1:944–949.
Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR,
Opgenorth TJ, Bova GS, Simons JW. 1996. Endothelin-1
production and decreased endothelin B receptor expres-
sion in advanced prostate cancer. Cancer Res 56:663–
668.
Nelson JB, Nguyen SH,Wu-Wong JR, Opgenorth TJ, Dixon
DB, Chung LW, Inoue N. 1999. New bone formation in an
osteoblastic tumor model is increased by endothelin-1
overexpression and decreased by endothelin A receptor
blockade. Urology 53:1063–1069.
NielsenOS,Munro AJ, Tannock IF. 1991. Bonemetastases:
Pathophysiology and management policy. J Clin Oncol
9:509–524.
Nifuji A, Noda M. 1999. Coordinated expression of noggin
and bone morphogenetic proteins (BMPs) during early
skeletogenesis and induction of noggin expression by
BMP-7. J Bone Miner Res 14:2057–2066.
Nifuji A, Kellermann O, Noda M. 1999. Noggin expression
in a mesodermal pluripotent cell line C1 and its
regulation by BMP. J Cell Biochem 73:437–444.
Oyajobi BO, Anderson DM, Traianedes K, Williams PJ,
Yoneda T, Mundy GR. 2001. Therapeutic efficacy of a
soluble receptor activator of nuclear factor kappaB–IgG
Fc fusion protein in suppressing bone resorption and
hypercalcemia in a model of humoral hypercalcemia of
malignancy. Cancer Res 61:2572–2578.
Papapoulos SE, Hamdy NA, van der Pluijm G. 2000.
Bisphosphonates in the management of prostate carci-
noma metastatic to the skeleton. Cancer 88:3047–3053.
Parfitt AM. 2000. The mechanism of coupling: A role for the
vasculature. Bone 26:319–323.
Patel KV, Schrey MP. 1995. Human breast cancer cells
contain a phosphoramidon-sensitive metalloproteinase
which can process exogenous big endothelin-1 to endothe-
lin-1: A proposed mitogen for human breast fibroblasts.
Br J Cancer 71:442–447.
Patel KV, Sheth HG, Schrey MP. 1997. Stimulation or
endothelin-1 secretion by human breast cancer cells
through protein kinase A activation: A possible novel
paracrine loop involving breast fibroblast-derived pros-
taglandin E2. Mol Cell Endocrinol 126:143–151.
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF,
Colman N, Michaeli J, Epstein J, Choi Y. 2001. Multiple
myeloma disrupts the TRANCE/osteoprotegerin cytokine
axis to trigger bone destruction and promote tumor
progression. Proc Natl Acad Sci USA 98:11581–11586.
Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL,
Beneton M, Kanis JA. 1987. Biochemical and histological
evidence that carcinoma of the prostate is associatedwith
increased bone resorption. Eur J Surg Oncol 13:41–49.
Perkel VS, Mohan S, Baylink DJ, Linkhart TA. 1990. An
inhibitory insulin-like growth factor binding protein (In-
IGFBP) from human prostatic cell conditioned medium
reveals N-terminal sequence identity with bone derived
In-IGFBP. J Clin Endocrinol Metab 71:533–535.
Pirtskhalaishvili G, Nelson JB. 2000. Endothelium-derived
factors as paracrine mediators of prostate cancer pro-
gression. Prostate 44:77–87.
Rabbani SA, Gladu J, Mazar AP, Henkin J, Goltzman D.
1997. Induction in human osteoblastic cells (SaOS2) of
the early response genes fos, jun, and myc by the amino
terminal fragment (ATF) of urokinase. J Cell Physiol
172:137–145.
Rana A, Chisholm GD, KhanM, Sekharjit SS, Merrick MV,
Elton RA. 1993. Patterns of bone metastasis and their
prognostic significance in patients with carcinoma of the
prostate. Br J Urol 72:933–936.
Raval P, Hsu HH, Schneider DJ, Sarras MP, Jr., Masuhara
K, Bonewald LF, Anderson HC. 1996. Expression of bone
morphogenetic proteins by osteoinductive and non-
osteoinductive human osteosarcoma cells. J Dent Res
75:1518–1523.
Reddi AH. 1997. Bone morphogenetic proteins: An uncon-
ventional approach to isolation of first mammalian
morphogens. Cytokine Growth Factor Rev 8:11–20.
Roland S. 1958. Calcium studies in ten cases of osteoblastic
prostatic metastasis. J Urol 79:339–342.
Roodman GD. 1996. Advances in bone biology: The
osteoclast. Endocr Rev 17:308–332.
Rosol TJ. 2000. Pathogenesis of bone metastases: Role of
tumor-related proteins. J Bone Miner Res 15:844–850.
Roudier M, Sherrard D, True L, Ott-Ralp S, Meligro C,
MBerrie M, Soo C, Felise D, Quinn JE, Vessella R. 2000.
Heterogenous bone histomorphometric patterns in meta-
static prostate cancer. J Bone Miner Res 15S1:S567.
Sasaki T, Hong MH. 1993a. Endothelin-1 localization in
bone cells and vascular endothelial cells in rat bone
marrow. Anat Rec 237:332–337.
Sasaki T, Hong MH. 1993b. Localization of endothelin-1 in
the osteoclast. J Electron Microsc (Tokyo) 42:193–196.
Schrey MP, Patel KV. 1995. Prostaglandin E2 production
and metabolism in human breast cancer cells and breast
fibroblasts. Regulation by inflammatory mediators. Br J
Cancer 72:1412–1419.
Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS,
Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T,
ShimamotoG,DeRoseM,Elliott R, ColomberoA, TanHL,
728 Keller and Brown
Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L,
Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ,
et al. 1997. Osteoprotegerin: A novel secreted protein
involved in the regulation of bone density. Cell 89:309–
319.
SollowayMJ, Dudley AT, Bikoff EK, Lyons KM, Hogan BL,
Robertson EJ. 1998. Mice lacking Bmp6 function. Dev
Genet 22:321–339.
Stern PH, Tatrai A, Semler DE, Lee SK, Lakatos P,
Strieleman PJ, Tarjan G, Sanders JL. 1995. Endothelin
receptors, second messengers, and actions in bone. J
Nutr 125:2028S–2032S.
Suzuki A, Kaneko E, Maeda J, Ueno N. 1997. Mesoderm
induction by BMP-4 and -7 heterodimers. Biochem
Biophys Res Commun 232:153–156.
Szostak MJ, Kyprianou N. 2000. Radiation-induced apop-
tosis: Predictive and therapeutic significance in radio-
therapy of prostate cancer (review). Oncol Rep 7:699–
706.
Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H,
DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas
SC. 1998. Interleukin-6-type cytokines stimulate
mesenchymal progenitor differentiation toward the
osteoblastic lineage. Proc Assoc Am Physicians 110:
559–574.
Takuwa Y, Masaki T, Yamashita K. 1990. The effects of the
endothelin family peptides on cultured osteoblastic cells
from rat calvariae. Biochem Biophys Res Commun
170:998–1005.
Thalmann GN, Anezinis PE, Chang S-M, Zhau HE, Kim
EE, Hopwood VL, Pathak S, Eschenbach ACv, Chung
LWK. 1994. Androgen-independent cancer progression
and bone metastasis in the LNCaP model of human
prostate cancer. Cancer Res 54:2577–2581.
Thomas RJ, Guise TA, Yin JJ, Elliott J, Horwood NJ,
Martin TJ, Gillespie MT. 1999. Breast cancer cells
interact with osteoblasts to support osteoclast formation.
Endocrinology 140:4451–448.
Tsuji K, Ito Y, Noda M. 1998. Expression of the PEBP2al-
phaA/AML3/CBFA1 gene is regulated by BMP4/7 hetero-
dimer and its overexpression suppresses type I collagen
and osteocalcin gene expression in osteoblastic and
nonosteoblastic mesenchymal cells. Bone 22:87–92.
Urwin GH, Percival RC, Harris S, Beneton MN, Williams
JL, Kanis JA. 1985. Generalised increase in bone
resorption in carcinoma of the prostate. Br J Urol 57:
721–723.
Vinholes J, Coleman R, Eastell R. 1996. Effects of bone
metastases on bone metabolism: Implications for diag-
nosis, imaging, and assessment of response to cancer
treatment. Cancer Treat Rev 22:289–331.
Wan M, Shi X, Feng X, Cao X. 2001. Transcriptional
mechanisms of BMP-induced osteoprotegrin gene expres-
sion. J Biol Chem 276:10119–10125.
Weber KL, Bolander ME, Rock MG, Pritchard D, Sarkar G.
1998. Evidence for the upregulation of osteogenic
protein-1 mRNA expression in musculoskeletal neo-
plasms. J Orthop Res 16:8–14.
Wlosarski K, Reddi AH. 1987. Tumor cells stimulate in vivo
periosteal bone formation. Bone Miner 2:185–192.
Wozney JM. 1992. The bone morphogenetic protein family
and osteogenesis. Mol Reprod Dev 32:160–167.
Wrana JL. 2000. Regulation of Smad activity. Cell
100:189–192.
Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Katagiri T,
Wozney JM, Rosen V, Yoshiki S. 1996. Effects of BMP-2,
BMP-4, and BMP-6 on osteoblastic differentiation of bone
marrow-derived stromal cell lines, ST2, and MC3T3-G2/
PA6. Biochem Biophys Res Commun 220:366–371.
Yamashita T, Yoshitake H, Tsuji K, Kawaguchi N,
Nabeshima Y, Noda M. 2000. Retardation in bone
resorption after bone marrow ablation in klotho mutant
mice. Endocrinology 141:438–445.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y,
Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T.
1988. A novel potent vasoconstrictor peptide produced by
vascular endothelial cells. Nature 332:411–415.
Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K,
Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M,
Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio
K. 1998a. Identity of osteoclastogenesis inhibitory factor
(OCIF) and osteoprotegerin (OPG): A mechanism by
which OPG/OCIF inhibits osteoclastogenesis in vitro.
Endocrinology 139:1329–1337.
Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki
M, Mochizuki S, Tomoyasu A, Yano K, Goto M,
Murakami A, Tsuda E, Morinaga T, Higashio K,
Udagawa N, Takahashi N, Suda T. 1998b. Osteoclast
differentiation factor is a ligand for osteoprotegerin/
osteoclastogenesis-inhibitory factor and is identical to
TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597–
3602.
Yin J, Grubbs B, Cui Y, Weu-Wong J, Wessale J, Padley R,
Guise T. 2000. Endothelin A receptor blockade inhibits
osteoblastic metastases. J Bone Miner Res 15:S201.
Yoneda T. 1998. Cellular and molecular mechanisms of
breast and prostate cancer metastasis to bone. Eur J
Cancer 34:240–245.
Yorimitsu K, Moroi K, Inagaki N, Saito T, Masuda Y,
Masaki T, Seino S, Kimura S. 1995. Cloning and
sequencing of a human endothelin converting enzyme
in renal adenocarcinoma (ACHN) cells producing
endothelin-2. Biochem Biophys Res Commun 208:721–
727.
Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C,
Mizokami A, Fu Z, Westman J, Keller ET. 2001.
Osteoprotegerin inhibits prostate cancer-induced osteo-
clastogenesis and prevents prostate tumor growth in the
bone. J Clin Invest 107:1235–1244.
Zimmerman LB, De Jesus-Escobar JM, Harland RM. 1996.
The Spemann organizer signal noggin binds and inacti-
vates bone morphogenetic protein 4. Cell 86:599–606.
Prostate Cancer Metastases Induce Bone Remodeling 729
